We have examined the effects of 1,25 dihydroxyvitamin D3 (1, 25[0HJ2D3) 
Introduction
Hypercalcemia is a common complication of human malignancy and may produce considerable morbidity and mortality.
Parathyroid hormone-related peptide (PTHRP)' is a recently described entity that has been shown to be a pathogenetic mediator of humoral hypercalcemia ofmalignancy (1) (2) (3) (4) (5) (6) . Hypercalcemia may also occur in association with a number of animal neoplasms. Among the best characterized of the animal models, and one which closely mimics the human syndrome, is the male Fischer rat implanted with the Rice 500 Leydig cell tumor (7, 8) . PTHRP is well documented to cause the hypercalcemia associated with this tumor (9, 10) . Currently, the mainstays of therapy for malignancy-associated hypercalcemia are agents that inhibit skeletal calcium mobilization, such as bisphosphonates and calcitonin, or agents that enhance renal calcium clearance, such as loop diuretics. However, PTHRP is known to cause hypercalcemia by its action on both bone and kidney. Consequently, a therapeutic strategy aimed at inhibiting PTHRP production and thereby neutralizing both mechanisms simultaneously might be a useful addition to our antihypercalcemic armamentarium. To date, no such strategy has been reported.
PTHRP expression has been shown to be regulated by multiple factors in a variety of human cell lines in vitro, including rat Leydig cells grown in culture. We have recently shown that in cultured Leydig cells several steroidal factors such as testosterone and dexamethasone inhibit PTHRP gene expression and secretion. The seco-steroid 1,25 dihydroxyvitamin D3 (1 ,25 [OH]2D3) is also inhibitory of PTHRP production in vitro both in this tumor and in other normal and malignant cell types (11) (12) (13) (14) . Nevertheless the in vivo efficacy of this substance is unknown. In the present study we have therefore examined the capacity of 1,25(OH)2D3 and of a low calcemic vitamin D analogue, EB 1089, to inhibit PTHRP production by the Rice 500 Leydig cell tumor in vivo and to prevent the development of hypercalcemia. Effects on body weight and tumor volume were also examined and the effect on animal survival time was assessed.
Methods
Vitamin D and analogue. 1,25-(OH)2D3 was a generous gift of Dr. M. Uskokovic of Roche Pharmaceuticals (Nutley, NJ). EB 1089 is an analogue of 1,25(OH)2D3 which was kindly provided by Leo Pharmaceuticals (Ballerup, Denmark) (15) .
Animal protocols. Male Fischer 344 rats (Charles River Breeding Laboratories, Inc., Wilmington, MA), weighing 200-220 g (10 wk of age), were used in all studies. Animals were housed individually and maintained on tap water ad lib. and standard rodent chow (rat chow 5012; Ralston-Purina Canada, Inc., Lasalle, Quebec, Canada) containing 1% calcium and 0.74% phosphorus (16) . The Rice-500 Leydig cell tumor was obtained from the National Cancer Institute Breast Cancer Task Force Bank (EEG Mason Research Institute, Worcester, MA). The tumor was minced in normal saline to give a suspension of one part oftumor to one part ofsaline. Tumor suspension (0.2 ml) was then injected into the right flank of each test animal. Control animals were weight matched and maintained under identical conditions (9) .
To examine the effect of 1,25(OH)2D3 and EB1089 on tumor-bearing animals, osmotic minipumps (model 2ML4 Alzet; Alza Corporation, Palo Alto, CA) were implanted intraperitoneally under light ether anesthesia. Each minipump contained either 1,25(OH)2D3 or EB 1089 dissolved in 1 ml of propylene glycol, 200 Ml of ethanol, and 800 Ml of saline to deliver a continuous dose ofthe compound for up to 4 wk at a delivery rate of 2.5 IAl/h (17) . On the day of tumor implantation all tumor-bearing animals also received a loading dose equivalent to one daily dose ofeither 1,25(OH)2D3 or EB 1089. One group oftumor-bearing animals received vehicle alone as a control. Other control groups of sham-operated animals without tumor received either 1,25(OH)2D3, EB 1089, or vehicle alone through osmotic minipumps as described above for up to 4 wk.
All animals were weighed every third day for up to 4 wk. Blood samples were collected every third day from each group under ether anesthesia and plasma samples were stored at -20'C until the time of analysis. The tumor mass of control and experimental animals was measured in two dimensions by calipers and the tumor volume was calculated (18) . Tumor tissue was also extracted for RNA analysis.
Analytical methods. Plasma calcium levels were determined by atomic-absorption spectrophotometry (model 703; Perkin-Elmer Corp., Norwalk, CT).
For RIA of PTHRP, rat plasma was tested in two dilutions in duplicate using an NH2-terminal RIA, as described previously (19) , and values were assigned using a PTHRP(l-34) standard. Consequently, all values are in picomole equivalents per liter relative to PTHRP . These samples were also tested in an NH2-terminal RIA kit (Incstar Corporation, Stillwater, MN), according to manufacturer's instructions.
For Northern blot analysis, 20Mgg oftotal RNA was electrophoresed on a 1.1% agarose-formaldehyde gel and transferred by blotting to a nylon membrane (20). The filters were hybridized (21) with an EcoRI, XbaI restriction fragment of PTHRP cDNA M-9 and a rat cyclophylin 800-bp pair BamHI restriction fragment from plasmid pCD15.8.1 (6, 22 (24) .
Results
Effects on hypercalcemia Effect of1,25(OH)2D3 and EBR1089 on plasma calcium. In nontumor-bearing animals the lowest dose of 1,25 (OH)2 D3 (50 pmol/24 h) did not produce significant hypercalcemia, however, higher doses produced a progressive increase in plasma calcium (Fig. 1, top) . In (Fig. 2, top) . Nevertheless, these animals did become hypercalcemic towards the end of experiment. In contrast, tumor-bearing animals infused with .200 pmol/24 h ofthe analogue maintained near-normal plasma levels comparable to the calcium levels of non-tumorbearing rats (Fig 2, bottom) . This effect was sustained throughout the infusion of this vitamin D analogue (Fig. 2, bottom) . (Fig. 3) . Animals receiving a low dose of 1,25 (OH)2D3 also displayed a gain in body weight, however, the higher doses induced a drop in body weight (Fig. 3, top) . In contrast all doses of EB 1089 permitted a progressive gain in weight over time that was parallel to the vehicle-treated control group in these non-tumor-bearing rats (Fig. 3, bottom) . Tumor-bearing animals receiving vehicle alone progressively decreased their weight during the study, and at day 18 after tumor implantation, all animals in this group died (Fig.  4) . Animals receiving 100 pmol/24 h of 1,25 (OH)2 D3 showed a more pronounced body weight decline than the control group, whereas the animals receiving 50 pmol/24 h of 1, 25 (OH)2 D3 had a less dramatic drop in body weight, which was noticeable only by day 18 (Fig. 4, top) . In contrast, all tumor- (Fig. 6) . Similar results were seen with 100 pmol/24 h of 1 ,25(OH)2D3.
Immunoreactive PTHRP (iPTHRP) was undetectable in non-tumor-bearing animals. However, all tumor-bearing animals had detectable concentrations ofplasma iPTHRP as of 12 d after tumor implantation and the levels progressively increased (Fig. 7) Effect of EB1089 on survival time. We next assessed the effect of either 1,25(OH)2D3 or its analogue EB 1089 on survival time of the tumor-bearing animals. Animals receiving vehicle alone generally died at day 18 after tumor implantation (Fig. 8) . Administration of 100 pmol/24 h of 1,25(OH)2D3 reduced the survival time whereas 50 pmol/24 h of 1,25(OH)2D3 produced a modest increase in survival. However, animals receiving the vitamin D analogue EB1089 displayed a more marked increase in survival time with the longest survival achieved in animals infused with the highest dose (400 pmol/ 24 h) of EB 1089. By day 20 after tumor implantation, few of the animals receiving the low dose of 1,25(OH)2D3 (50 pmol/ 24 h) survived whereas 100% of the animals receiving 400 pmol/24 h of EB1089 and 84% of the animals receiving 200 pmol/24 h of EB 1089 survived. By day 24, at which time none of the animals in the other groups were alive, 67% of the animals receiving 400 pmol/24 h of EB 1089 had survived (Fig. 8) .
Discussion
In recent years novel nonhypercalcemic actions of 1,25-(OH)2D3 have been reported. Among these is a potent antiproliferative effect, which could be of potential therapeutic benefit in cancer states (25) (26) (27) . However, the inherent hypercalcemic activity of 1,25(OH)2D3 has prevented its use as a potential therapeutic agent in this regard. Recently, intense efforts have resulted in the development of several 1,25(OH)2D3 analogues that exhibit low calcemic activity. The major modifications of 1,25(OH)2D3 that have resulted in low calcemic analogues have been structural changes in the side chain, such as introduction of oxygen atoms and stereochemical changes (27) (28) (29) . We have used one such analogue, EB1089, in our studies. In this analogue the side chain has been elongated with introduction ofterminal ethyl groups and double bonds have been introduced at positions 22 and 24 (16) . Low calcemic analogues of vitamin D retain the antiproliferative effects of 1,25(OH)2D3 but are far less active in absorption of intestinal calcium and mobilization of calcium from bone (28) . Indeed EB1089 has previously been reported to be 60 times more active in inhibiting cell proliferation and inducing cell differentiation than 1,25(OH)2D3 in U937 histiocytic lymphoma cells in vitro while having a threefold lower calciuric activity in normal rats in vivo (30) . In addition, in common with 1,25(OH)2D3, several ofthe low calcemic analogues may decrease the synthesis of parathyroid hormone, induce osteocalcin gene expression in bone cells, inhibit angiogenesis, and display immunoregulatory activity (29, (31) (32) (33) . Administration of such 1,25(OH)2D3 analogues either orally, intraperitoneally, or by direct injection into tumor tissue has been shown in certain models to decrease tumor volume and prolong animal survival without causing hypercalcemia (27, 28, 34) .
We compared the capacity of 1 ,25(OH)2D3 and of EB 1089 to control the syndrome of malignancy-associated hypercalcemia in vivo. The rationale ofthis approach was primarily made on the basis of our previous demonstration that both 1, 25 Analysis of PTHRP mRNA levels in the tumor confirmed our hypothesis that 1 ,25(OH)2D3 and its analogue could inhibit PTHRP gene expression in vivo as well as in vitro. This inhibition was unlikely to be simply due to the antiproliferative effects of these agents, inasmuch as mRNA encoding PTHRP was selectively reduced relative to cyclophylin mRNA. In vitro, at least part of the inhibitory effect of vitamin D appears to be at the level of PTHRP gene transcription (1 1). Whether similar molecular mechanisms are involved in the in vivo inhibitory actions of vitamin D and its analogue remains to be determined. Circulating levels of iPTHRP were also diminished by 1,25(OH)2D3 and its analogue in keeping with its inhibitory effect on PTHRP secretion in vitro. Although iPTHRP concentrations were reduced as compared with control tumor-bearing animals, they were not completely suppressed. This nonsuppressible immunoreactivity may represent biologically inert NH2-terminal material or may represent a level of biologically active PTHRP whose hypercalcemic activity may be neutralized by compensatory mechanisms. An analogous situation has been reported in humans with tumors in which elevated circulating concentrations of PTHRP have been described in association with normocalcemia (19, 37, 38) .
We have also examined beneficial antineoplastic properties of 1,25(OH)2D3 and EB 1089 other than inhibition of PTHRP production. A reduction in tumor volume was observed with both the lowest dose of 1,25(OH)2D3 used as well as with the higher dose of analogue used. Such a reduction may well have been due to the antiproliferative activity ofboth vitamin D and its analogue. However, even in the absence of severe hypercalcemia, the low dose of 1,25(OH)2D3 was unable to prevent weight loss after day 12 and survival time was markedly lower than with the higher concentrations of analogue that could be used. These results suggest that the analogue may have additional properties at the concentration used, such as the inhibition of other tumor products that contribute to cachexia and death. Further studies will be required to evaluate these possibilities.
